Three insights:
1. DSUVIA, a synthetic opioid tablet, received FDA approval in 2018.
2. The study will explore if DSUVIA is linked with a decrease in pain intensity in the recovery room, opioid consumption and side effects, number of IV fentanyl boluses and hospitalization costs.
3. Richard Urman, MD, associate professor of anesthesia and co-director of the center for perioperative research at BWH and Boston-based Harvard Medical School is leading the study.
More articles on spine:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.